Marker Therapeutics, Inc. (MRKR)
1.50
+0.11
(+7.91%)
USD |
NASDAQ |
Aug 24, 16:00
1.50
0.00 (0.00%)
After-Hours: 20:00
Marker Therapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | 0.00% |
| September 30, 2025 | 0.00% |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | 0.00% |
| September 30, 2024 | 0.00% |
| June 30, 2024 | 0.00% |
| March 31, 2024 | 0.00% |
| December 31, 2023 | 0.00% |
| September 30, 2023 | 0.00% |
| June 30, 2023 | 0.00% |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -6.12% |
| March 31, 2022 | 13.49% |
| December 31, 2021 | 33.95% |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | 0.00% |
| March 31, 2020 | |
| December 31, 2019 | 0.00% |
| Date | Value |
|---|---|
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 93.46% |
| Tenaya Therapeutics, Inc. | -52.97% |
| Ironwood Pharmaceuticals, Inc. | 99.60% |
| Vericel Corp. | 72.82% |
| SELLAS Life Sciences Group, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -60.77% |
| Return on Assets | -49.70% |
| Return on Invested Capital | -60.77% |